Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Prism Venture Partners
AddedFeb 15, 2024
UpdatedJun 28, 2026
Prism Venture Partners

Prism Venture Partners

Operating

Prism Venture Management: A US-based venture capital firm investing in tech, life sciences, gaming, healthcare, and e-commerce.

Location
Needham, MA, US
Founded
1996
Firm
Compare
Portfolio
Employees

Investments

Osteal Therapeutics
Osteal Therapeutics

Total Raised

$62.8M

Rounds

4

Series C$23MSeptember 2023
Babson Diagnostics
Babson Diagnostics

Total Raised

$44.7M

Rounds

2

Series B$31MJune 2021
Series A$13.7MSeptember 2020
The Receivables Exchange
The Receivables Exchange

Total Raised

$39.8M

Rounds

5

Private Equity$10MJune 2013
Series C$17MJanuary 2010
Series B$7.8MFebruary 2009
Series A$5MOctober 2007
White Sky
White Sky

Total Raised

$26.5M

Rounds

4

Series Unknown$7.5MJune 2012
Series B$11MSeptember 2008
Lifecrowd
Lifecrowd

Total Raised

$5M

Rounds

1

Series A$5MApril 2012
Sparkplay Media
Sparkplay Media

Total Raised

$7M

Rounds

2

Series Unknown$2.8MJanuary 2010
Series A$4.3MFebruary 2008
Six Degrees Games
Six Degrees Games

Total Raised

$18M

Rounds

3

Series B$7MNovember 2009
Series A$7MJuly 2008
Rox Medical
Rox Medical

Total Raised

$96.7M

Rounds

6

Series C$33MJune 2008
Series B$10.1MJuly 2006
Mota Group
Mota Group
Public

Total Raised

$9.5M

Rounds

3

Series A$4.5MApril 2008
Expo
Expo

Total Raised

$6M

Rounds

2

Series BJuly 2007
Series A$6MDecember 2006
Worldwide Biggies
Worldwide Biggies

Total Raised

$10M

Rounds

2

Series A$9MApril 2007
SiCortex
SiCortex

Total Raised

$53.1M

Rounds

4

Series B$21MOctober 2006
Peptimmune
Peptimmune

Total Raised

$92.9M

Rounds

6

Series C$12MJune 2006
Everypoint
Everypoint
Acquired

Total Raised

$14M

Rounds

2

Series B$10MMarch 2006
Insulet
Insulet
Public

Total Raised

$179.5M

Rounds

7

Series E$50MFebruary 2006
Optiscan Biomedical
Optiscan Biomedical

Total Raised

$165M

Rounds

7

Series Unknown$36MOctober 2005